ADAM17 and metabolic dysfunction-associated steatohepatitis: ADAM17 cleavage-resistant mice show gain-of-function activity in NASH, leading to pathological fibrosis [12,62] and protective therapeutic values in clearing atherosclerotic plaques [39,51], suggesting complex phenotypic outcomes.